Skip to main content
Mignon Loh, MD, Pediatric Hematology & Oncology, Seattle, WA, UCSF Medical Center

MignonL.LohMD

Pediatric Hematology & Oncology • Seattle, WA

Chief, Division of Pediatric Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy & Director, Ben Towne Center for Childhood Cancer

Join to view full profile

Dr. Loh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Loh's full profile

Already have an account?

Summary

  • Dr. Mignon Loh is center director for the Ben Towne Center for Childhood Cancer Research and chief of the Division of Pediatric Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy, overseeing the Cancer and Blood Disorders Center at Seattle Children’s Hospital. Her research focuses on how and why leukemia progresses, as well as making genomics discoveries in the lab that translate into new and better diagnostics and therapeutics for children, adolescents and young adults with leukemia.

Education & Training

  • Children's Hospital/Boston Medical Center
    Children's Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1995 - 1998
  • Children's Hospital/Boston Medical Center
    Children's Hospital/Boston Medical CenterResidency, Pediatrics, 1992 - 1994
  • University of California (San Francisco)
    University of California (San Francisco)Internship, Pediatrics, 1991 - 1992
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 1991

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2021 - 2026
  • CA State Medical License
    CA State Medical License 1999 - 2025
  • MA State Medical License
    MA State Medical License 1994 - 2001
  • NC State Medical License
    NC State Medical License 1995 - 1998
  • NY State Medical License
    NY State Medical License 1994 - 1996
  • CT State Medical License
    CT State Medical License 1994 - 1995
  • American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Inotuzumab Ozogamicin in Pediatric Patients with relapsed/refractory Acute Lymphoblastic Leukemia  
    Deepa Bhojwani, Constance Yuan, Jennifer L McNeer, Mignon L Loh, Vilmarie Rodriguez, Susan R Rheingold, Elizabeth A Raetz, Nature
  • Downregulating Notch Counteracts KrasG12D-Induced ERK Activation and Oxidative Phosphorylation in Myeloproliferative Neoplasm  
    Erik A Ranheim, David Yang, Warren S Pear, Lan Zhou, Mignon Loh, Eric Padron, Elliot Stieglitz, Nature
  • Mutation-Specific Signaling Profiles and Kinase Inhibitor Sensitivities of Juvenile Myelomonocytic Leukemia Revealed by Induced Pluripotent Stem Cells  
    Stella T Chou, Jessica A Casas, Mignon L Loh, Sarah K Tasian, Nature
  • Join now to see all

Abstracts/Posters

  • RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia
    Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...
    Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia
    Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Using Genomics to Risk Stratify and Treat Kids 
    60th American Society of Hematology Annual Meeting - 12/2/2018
  • Using Genomics to Risk Stratify and Treat Kids 
    60th American Society of Hematology Annual Meeting - 12/1/2018
  • Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Taking Stock of Breakthroughs and Struggles in Pediatric Cancer Care
    Taking Stock of Breakthroughs and Struggles in Pediatric Cancer CareJuly 1st, 2022
  • Seattle Children’s Welcomes Dr. Mignon Loh to Lead Cancer and Blood Disorders Care and Research
    Seattle Children’s Welcomes Dr. Mignon Loh to Lead Cancer and Blood Disorders Care and ResearchFebruary 1st, 2022
  • IU Researcher Leads National Work Focused on Developing Treatments for Inherited Childhood Cancers
    IU Researcher Leads National Work Focused on Developing Treatments for Inherited Childhood CancersNovember 18th, 2021
  • Join now to see all

Grant Support

  • International Symposium On Juvenile Myelomonocytic Leukemia (JMML)National Cancer Institute2011
  • International Symposium On Juvenile Myelomonocytic Leukeumia (JMML)National Cancer Institute2010
  • Identifying The Spectrum Of Genetic Alterations In High Risk AllNational Cancer Institute2010
  • Targeted Therapies For Childhood Acute Lymphoblastic LeukemiaNational Cancer Institute2009–2010
  • International Symposium On Juvenile Myelomonocytic LeukemiaNational Cancer Institute2007–2009
  • RAS Pathway Mutations In Human LeukemiaNational Cancer Institute2006–2008
  • OPEN Label, Phase I/II Trial Of Rituximab For Chronic, Severe ITPNational Center For Research Resources2004–2005
  • Fusion Genes In Leukemia--Determining SignificanceNational Cancer Institute1999–2003
  • Fusion Genes In Leukemia--Determining SignificanceNational Cancer Institute1999

Hospital Affiliations

Dr. Mignon Loh, Dr. Mignon Loh, MD, Dr. M Loh, Dr. Mignon L. Loh